



Contact:

Eric Richman
V.P. Corporate Development
MaxCyte, Inc.
(301) 517-5556

For Immediate Release

R. Michael Blaese, M.D. Joins MaxCyte™ Scientific Advisory Board

Rockville, MD, February 27, 2002- MaxCyte today announced it has named R. Michael Blaese, M.D., a world recognized leader in gene and cell therapy, as the newest member of its Scientific Advisory Board.

Dr. Blaese has over 35 years of experience in biomedical research in the areas of genetics and immunodeficiency, cell and gene therapy in both academic and private sector settings. Currently, Dr. Blaese is Vice President Research and Development, and Chief Medical Officer of PreGentis. Prior, Dr. Blaese was on the staff of the National Institutes of Health (NIH) for 33 years where his work spanned from basic research to the development of innovative therapies in a range of areas including immune function, virology, cancer, and molecular genetics.

In 1984, Dr. Blaese and Dr. French Anderson joined forces to develop the use of genes as medicines, a pioneering collaboration that led to the first successful human gene therapy in 1990. As Chief of Gene Therapy for the Human Genome Project, Dr. Blaese continued to set the pace in the early development of gene therapy, introducing clinical trials for inherited immunodeficiency, brain cancer, metabolic disorders and AIDS. He has published over 325 original research papers and was instrumental in policy formation governing gene therapy in the US at the NIH, FDA and the RAC (Recombinant DNA Advisory Committee).

Dr. Joseph Fratantoni, MaxCyte's Chief Medical Officer, commented, "The addition of Dr. Blaese to MaxCyte's Scientific Advisory Board further strengthens our commitment to the next generation of gene-based medicines. Dr. Fratantoni continued, "We look forward to continuing our work with Dr. Blaese in developing innovative therapies using MaxCyte's non-viral cell loading program. Dr. Blaese's unique clinical experience will be instrumental to helping patients with unmet medical needs."

According to Dr. Blaese, "The emergence of gene therapy has been hampered severely by the toxicities and regulatory concerns associated with currently available vectors and cumbersome cell processing. MaxCyte's technology, a closed system being developed for near patient treatment, avoids these concerns and has the potential to be the cornerstone of gene transfer in clinical medicine. I have collaborated with MaxCyte scientists and look forward to serving in an advisory role."

The MaxCyte Advisory Board is comprised of internationally recognized scientists with research and clinical expertise in the areas of cell permeation, red cell biology and gene based medicine. Dr. Blaese joins Malcolm Brenner, M.D., Ph. D., on MaxCyte's Scientific Advisory Board in the area of gene-based medicine. Dr. Brenner is the Current President of the American Society of Gene Therapy and Director, Center for Cell and Gene Therapy, Baylor College of Medicine.

MaxCyte is a clinical stage biotechnology company developing targeted therapeutic products to treat severe and chronic diseases, including cancer, serious infections, cardiovascular disease and genetic disorders, based on its proprietary technology that uses blood cells for drug and non-viral gene delivery. MaxCyte is majority owned by EntreMed, Inc. For further information, please visit the MaxCyte web site at <http://www.MaxCyte.com>.

EntreMed, Inc., The Angiogenesis Company(TM), (NASDAQ: ENMD) is a clinical-stage biopharmaceutical company developing angiogenesis therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer, blindness and atherosclerosis. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories. For further information, please visit the EntreMed web site at <http://www.entremed.com>.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

####